- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NICE Turns Around to Support the Use of Celgene's Revlimid
The cost regulator for the NHS in England and Wales has said that Celgene's Revlimid should be an option for treating patients with a particular form of myelodysplastic syndromes.
In new final draft guidance, the National Institute for Health and Care Excellence (NICE) has recommended use of Revlimid (lenalidomide) in a specific type of MDS that is characterised by a chromosomal abnormality called an isolated deletion 5q cytogenetic abnormality. Currently, the main treatment option for people with this kind of MDS is best supportive care including regular blood transfusions.
In earlier draft guidances published this May and in June last year, NICE had not backed Revlimid in this use because, while the Institute’s appraisal committee had found it to be an effective therapy, the data provided by Celgene showed uncertainty about whether it actually extended lives. The June 2013 draft guidance had also opened a consultation.
Link to the original report: http://bit.ly/1pf6gSi
Source: PharmaTimes
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
